Dasatinib Accord

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

dasatinib

Disponibbli minn:

Accord Healthcare S.L.U.

Kodiċi ATC:

L01EA02

INN (Isem Internazzjonali):

dasatinib (anhydrous)

Grupp terapewtiku:

Antineoplastic agents

Żona terapewtika:

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Indikazzjonijiet terapewtiċi:

Dasatinib Accord is indicated for the treatment of adult patients with:• Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy.Dasatinib Accord is indicated for the treatment of paediatric patients with:• newly diagnosed Ph+ ALL in combination with chemotherapy.

Sommarju tal-prodott:

Revision: 1

L-istatus ta 'awtorizzazzjoni:

Withdrawn

Data ta 'l-awtorizzazzjoni:

2022-03-24

Fuljett ta 'informazzjoni

                                49
B. PACKAGE LEAFLET
Medicinal product no longer authorised
50
PACKAGE LEAFLET: INFORMATION FOR THE USER
DASATINIB ACCORD 20 MG FILM-COATED TABLETS
DASATINIB ACCORD 50 MG FILM-COATED TABLETS
DASATINIB ACCORD 70 MG FILM-COATED TABLETS
DASATINIB ACCORD 80 MG FILM-COATED TABLETS
DASATINIB ACCORD 100 MG FILM-COATED TABLETS
DASATINIB ACCORD 140 MG FILM-COATED TABLETS
dasatinib
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dasatinib Accord is and what it is used for
2.
What you need to know before you take Dasatinib Accord
3.
How to take Dasatinib Accord
4.
Possible side effects
5.
How to store Dasatinib Accord
6.
Contents of the pack and other information
1.
WHAT DASATINIB ACCORD IS AND WHAT IT IS USED FOR
Dasatinib Accord contains the active substance dasatinib. This
medicine is used to treat Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). It is
used in adults who are not
benefiting from previous therapies, as well as being combined with
other cancer medicines in
adolescents and children from 1 year of age with newly diagnosed Ph+
ALL. In people with ALL,
white cells called lymphocytes multiply too quickly and live too long.
Dasatinib Accord inhibits the
growth of these leukaemic cells.
If you have any questions about how Dasatinib Accord works or why this
medicine has been
prescribed for you, ask your doctor.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DASATINIB ACCORD
_ _
DO NOT TAKE DASATINIB ACCORD
-
if you are
ALLERGIC
to dasatinib or any of the other ingredients of 
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Dasatinib Accord 20 mg film-coated tablets
Dasatinib Accord 50 mg film-coated tablets
Dasatinib Accord 70 mg film-coated tablets
Dasatinib Accord 80 mg film-coated tablets
Dasatinib Accord 100 mg film-coated tablets
Dasatinib Accord 140 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dasatinib Accord 20 mg film-coated tablets
Each film-coated tablet contains 20 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 27 mg of lactose (as monohydrate).
Dasatinib Accord 50 mg film-coated tablets
Each film-coated tablet contains 50 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 67.5 mg of lactose (as monohydrate).
Dasatinib Accord 70 mg film-coated tablets
Each film-coated tablet contains 70 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 94.5 mg of lactose (as monohydrate).
Dasatinib Accord 80 mg film-coated tablets
Each film-coated tablet contains 80 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 108 mg of lactose (as monohydrate).
Dasatinib Accord 100 mg film-coated tablets
Each film-coated tablet contains 100 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 135.0 mg of lactose (as monohydrate).
Dasatinib Accord 140 mg film-coated tablets
Each film-coated tablet contains 140 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 189 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Dasatinib Accord 20 mg film-coated tablets
Medicinal product no longer authorised
3
White to off-white, round, 5.6 mm of diameter, coated tablets debossed
on one side with "DAS" and
"20" on the other side.
Dasatinib Accord 50 mg film-coated tablets
White to off-white, oval, 5.7 x 10.6 mm, coated tablets debossed on
one side with "DAS" and "50" on
the other
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 30-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 30-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 30-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 30-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 30-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 30-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 30-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 30-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 30-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 30-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 30-03-2023

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti